MedTrace Logo

Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)

NCT00826228 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-07-11

Study results available
· View outcomes & findings →

Summary

Individuals with spinal cord injury sustain significant loss of bone mass in their lower extremities (20-40% or more). This study evaluates the ability of PTH and weight-bearing, two interventions that build bone, to increase bone mass in this population.

Conditions

Interventions

DRUG

teriparatide

teriparatide 20ug daily sc for 6 months

OTHER

weight-bearing

device assisted walking

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Shirley Ryan AbilityLab

    collaborator OTHER

  • Thomas J. Schnitzer

    lead OTHER

Principal Investigators

  • Thomas J Schnitzer, MD, PhD · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-03-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00826228 on ClinicalTrials.gov